Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2009 | 09-2009 | 06-2009 | 03-2009 | 12-2008 | |
| Sales | 87,082 | 80,807 | 82,787 | 73,980 | 99,277 |
| Cost of Goods | 16,729 | 14,970 | 19,848 | 14,362 | 11,665 |
| Gross Profit | 70,353 | 65,837 | 62,939 | 59,618 | 87,612 |
| Operating Expenses | 64,700 | 56,674 | 59,474 | 64,381 | 56,220 |
| Operating Income | 6,382 | 10,133 | 4,313 | -4,401 | 32,057 |
| Interest Expense | 2,719 | 2,880 | 4,404 | 4,087 | 4,098 |
| Other Income | 219 | 332 | 1,925 | -4,247 | -1,403 |
| Pre-tax Income | 3,882 | 7,585 | 1,834 | -12,735 | 26,556 |
| Income Tax | -830 | 945 | 522 | 417 | 2,050 |
| Net Income Continuous | 4,712 | 6,640 | 1,312 | -13,152 | 24,506 |
| Net Income | $4,712 | $6,640 | $1,312 | $-13,152 | $24,506 |
| EPS Basic Total Ops | 0.05 | 0.07 | 0.01 | -0.13 | 0.24 |
| EPS Basic Continuous Ops | 0.05 | 0.07 | 0.01 | -0.13 | 0.25 |
| EPS Diluted Total Ops | 0.05 | 0.07 | 0.01 | -0.13 | 0.22 |
| EPS Diluted Continuous Ops | 0.05 | 0.07 | 0.01 | -0.13 | 0.24 |
| EBITDA(a) | $12,197 | $15,804 | $10,785 | $59 | $35,782 |